Gilead Shares Fall After Study Announcement


Salon Staff
February 17, 2012 6:54PM (UTC)

FOSTER CITY, Calif. (AP) — Shares of Gilead Sciences are sinking in pre-market trading. The drugmaker says a promising hepatitis C treatment it recently acquired may have to be used with other drugs in patients with the disease.

The Foster City, Calif., company said Friday that some patients in a small part of a mid-stage study relapsed within a month of completing the treatment. The potential drug is labeled GS-7977, and Gilead is studying it in hepatitis C patients with genotype 1, the most prevalent subset of the disease in the Western world and the hardest to treat.

Advertisement:

Hepatitis C can lead to life-threatening liver damage.

Gilead acquired the potential treatment in an $11 billion deal for Pharmasset Inc.

Shares of Gilead are down $9.97, or 18.2 percent, to $44.84 in pre-market trading.


Salon Staff

MORE FROM Salon Staff

BROWSE SALON.COM
COMPLETELY AD FREE,
FOR THE NEXT HOUR

Read Now, Pay Later - no upfront
registration for 1-Hour Access

Click Here
7-Day Access and Monthly
Subscriptions also available
No tracking or personal data collection
beyond name and email address

•••


Fearless journalism
in your inbox every day

Sign up for our free newsletter

• • •